Towards a myeloablative regimen with clinical potential: I. Treosulfan conditioning and bone marrow transplantation allow induction of donor-specific tolerance for skin grafts across full MHC barriers

This publication has 31 references indexed in Scilit:

• Inhibition of natural killer cells results in acceptance of cardiac allografts in CD28−/− mice
  Nature Medicine, 2001
• Treosulfan is an effective alkylating cytostatic for malignant melanoma in vitro and in vivo
  Melanoma Research, 1999
• DNA alkylation and interstrand cross-linking by treosulfan
  British Journal of Cancer, 1998
• Treosulfan as an Effective Second-Line Therapy in Ovarian Cancer
  Gynecologic Oncology, 1998
• Specific Tolerance Induction and Organ Transplantation
  Leukemia & Lymphoma, 1998
• Immunosuppression and risk of non-melanoma skin cancer in renal transplant recipients
  The Lancet, 1997
• PROGRESSIVE HISTOLOGIC INJURY IN KIDNEYS FROM HEART AND LIVER TRANSPLANT RECIPIENTS RECEIVING CYCLOSPORINE
  Transplantation, 1996
• Antitumor activity of treosulfan in human lung carcinomas
  Cancer Chemotherapy and Pharmacology, 1995
• ANTI-CD3 TREATMENT FACILITATES ENGRAFTMENT OF FULL H-2-DISPARATE DONOR BONE MARROW CELLS AND SUBSEQUENT SKIN ALLOGRAFT TOLERANCE
  Transplantation, 1994
• Mixed chimerism and permanent specific transplantation tolerance induced by a nonlethal preparative regimen.
  The Journal of Experimental Medicine, 1989